Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Miles, D.; de haas, S.; Dirix, L.; Romieu, G.; Chan, Arlene; Pivot, X.; Tomczak, P.; Provencher, L.; Cortes, J.; Delmar, P.; Scherer, S.

Access Status

Fulltext not available

Authors

Miles, D.

de haas, S.

Dirix, L.

Romieu, G.

Chan, Arlene

Pivot, X.

Tomczak, P.

Provencher, L.

Cortes, J.

Delmar, P.

Scherer, S.

Date

2013

Type

Journal Article

Metadata

Show full item record

Citation

Miles, D. and de haas, S. and Dirix, L. and Romieu, G. and Chan, A. and Pivot, X. and Tomczak, P. et al. 2013. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. British Journal of Cancer. 108: pp. 1052-1060.

Source Title

British Journal of Cancer